Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Listen to this summary
The authors of the MATTERHORN trial aimed to evaluate the impact of perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) on overall survival in patients with resectable gastric and gastro-oesophageal junction adenocarcinoma. The study found that overall survival significantly improved in the durvalumab group compared to the placebo group, establishing durvalumab plus FLOT as a new standard treatment option for this patient population.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Sep 22, 2026 · Lancet (London, England)
Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment
Sep 22, 2026 · Lancet (London, England)
Understanding peripheral arterial disease in the current era
Sep 22, 2026 · Lancet (London, England)
Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead
Sep 21, 2026 · Lancet (London, England)
Developing roadmaps for advancing practice, research, and policy in the arts and health
Sep 18, 2026 · Lancet (London, England)
Precision prevention and early detection: framework for a new clinical cancer control pathway
Sep 17, 2026 · Lancet (London, England)
Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
More in Nuclear Medicine
View all →Sep 23, 2026 · The New England journal of medicine
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Sep 23, 2026 · The New England journal of medicine
Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome
Sep 23, 2026 · The New England journal of medicine
Clinical Uses of Common Genetic Variants Associated with Common Diseases
Sep 23, 2026 · The New England journal of medicine
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
Sep 18, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
CMR and FDG PET/CT Imaging Phenotypes and their Association with Outcomes in Patients with Known or Suspected Myocarditis
Sep 14, 2026 · The New England journal of medicine
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
